PI-103

PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

Price Stock Quantity  
USD 134 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PI-103 Chemical Structure

PI-103 Chemical Structure
Molecular Weight: 348.36

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

PI3K Inhibitors with Unique Features

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • PI-103 Mechanism

Product Description

Biological Activity

Description PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.
Targets p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)

 View  More

IC50 2 nM 3 nM 3 nM 15 nM
In vitro PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BENYTTdHQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfPNE05KM7:TR?=M2LTTFI1NzR6L{eyJIg>NIizSohqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4ToMUOyOlIzPDZ6MR?=
SH-SY5YNYjnOJZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUm4O2pFOC16IN88US=>M2XLd|I1NzR6L{eyJIg>NV\2fGN7cW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=>NXLx[GtnOjZ{MkS2PFE>
SH-SY5Y NV;0N3p{SXCxcITvd4l{KEG|c3H5NITVbXkyKM7:TR?=M4jz[lAvPS1{NDDoMYXz[Y5{cXSrenXzJI5mfXKxYnzhd5RwdWFiY3XscJMhfG9iZH;4c5J2[mmlaX6tbY5lfWOnZDDhdI9xfG:|aYO=MkWzNlYzOjR4OEG=
G 35 SCNH;se4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTRNE4xPS1{MDFOwG0>M{OwRlI1Nzd{IHi=MUjEUXNQMX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6M4LTcVI3OTJzMkWx
G 38 SCNUPkXW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4H0WVAvODVvMkCg{txOM2fn[VI1Nzd{IHi=MWXEUXNQNHfwPXdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7NHq4W5QzPjF{MUK1NS=>
G 40 SCMkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWKwMlA2NTJyIN88US=>M4\pdlI1Nzd{IHi=MWHEUXNQNHqxWJVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7MWqyOlEzOTJ3MR?=
G 35 DCMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfVb|cxNjB3LUKwJO69VQ>?MoPQNlQwPzJiaB?=NWj2OldvTE2VTx?=M2rNV4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?M{nYOlI3OTJzMkWx
G 38 DCNYrLVoc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7CV28xNjB3LUKwJO69VQ>?MUWyOE84OiCqM3HBcWROW09?NF71bFRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7MX:yOlEzOTJ3MR?=
G 40 DCNVPYdlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlf5NE4xPS1{MDFOwG0>NEjCWVAzPC95MjDoM{O3XWROW09?NYnye214cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=MXOyOlEzOTJ3MR?=
RDNFqyRldCeG:ydH;zbZMhSXO|YYm=Ml\2NU8yNjVxMjFOwG0>NYDpdWhMPzJiaB?=NF\KPFRqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>?NW[wNGZ5OjV5NEmzO|g>
TE381.TNGmxPZVCeG:ydH;zbZMhSXO|YYm=M1jnd|EwOS53L{Kg{txOMoXvO|IhcA>?NGXvV4lqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>?MnHjNlU4PDl|N{i=
RMS13MlHDRZBweHSxc3nzJGF{e2G7Mn3uNU8yNjVxMjFOwG0>MoLTO|IhcA>?NYn0SpNTcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF?NXfhWpdJOjV5NEmzO|g>
RH30 M{fofGFxd3C2b4Ppd{BCe3OjeR?=M1flZVEwOS53L{Kg{txOM37VOVczKGh?MnPKbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE>MXGyOVc1QTN5OB?=
VJMX\BdI9xfG:|aYOgRZN{[Xl?MYexM|EvPS9{IN88US=>NYjoS2c1PzJiaB?=NHvQb5hqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>?MYCyOVc1QTN5OB?=
HS578TMX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>NHiySYMxNTNizszNMkHpO|IhcA>?M13NTolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?M4PSblI2PzJzNEG5
BT549Ml6xR4VtdCCYaXHibYxqfHliQYPzZZk>NUXhc|l7OC1|IN88US=>NGLIe4E4OiCqMU\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6MX2yOVczOTRzOR?=
MDA-MB-231NXO5WppyS2WubDDWbYFjcWyrdImgRZN{[Xl?NFXuPVYxNTNizszNM4HsPVczKGh?M{nQPYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?MVWyOVczOTRzOR?=
MDA-MB-468M{L5Z2NmdGxiVnnhZoltcXS7IFHzd4F6NYezWY1rOC1|IN88US=>MYe3NkBpNGPFOmFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7MYWyOVczOTRzOR?=
MDA-MB-436NW\qUJAzS2WubDDWbYFjcWyrdImgRZN{[Xl?NIH1c4wxNTNizszNNIntcVU4OiCqNX3XfHAycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=NXrhfVdNOjV5MkG0NVk>
SUM149PTMVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MYKwMVMh|ryPM3n2W|czKGh?NGTHfXRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7NEPTPFczPTd{MUSxPS=>
MDA-MB-468NYe5RnNJTnWwY4Tpc44hSXO|YYm=NFLFVWkxNjBzLUGwJO69VQ>?MVeyOEBpM3Lie4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB?NYCwd49sOjV5MkG0NVk>
MDA-MB-231MYrGeY5kfGmxbjDBd5NigQ>?Mo\2NE4xOS1zMDFOwG0>MUCyOEBpM2PONIRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB?MWKyOVczOTRzOR?=
HS578TMmXISpVv[3Srb36gRZN{[Xl?NWPFO2dKOC5yMT2xNEDPxE1?NGTpbFYzPCCqM1f4NYRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB?NY\yZ|ZGOjV5MkG0NVk>
SW872NWP0N5M2TnWwY4Tpc44hSXO|YYm=NW[xTJpSOC5yMT2wMlUh|ryPNUf6bFZIOjRiaB?=NVfydW1CemWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>M{jYelI1Pjl3NkOy
SW982NEOxZW9HfW6ldHnvckBCe3OjeR?=MlnxNE4xOS1yLkWg{txONEntd5czPCCqM17SSZJm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMgNHHOfpczPDZ7NU[zNi=>
SW872NXfZTnFwSXCxcITvd4l{KEG|c3H5MmrONE4xOS1yLkWg{txOMmTtOFghcA>?MV\pcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7M1n5SlI1Pjl3NkOy
SW982MWjBdI9xfG:|aYOgRZN{[Xl?MYqwMlAyNTBwNTFOwG0>M2T3SVQ5KGh?NXKwUXZIcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=>NYrKV|F2OjR4OUW2N|I>
AGS HGNEH1folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXq4OmtlUUN3ME2wMlY5KMLzIECuNFMyKM7:TR?=NWnDVYtjOjR3OUe0O|g>
AGS LGNHnBNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI[zXXRKSzVyPUCuNFUhyrFiMD6wNFEh|ryPNYTIN4ZsOjR3OUe0O|g>
HGC27 HGM2rUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwM{igxtEhOC5yMkKg{txOM{f6R|I1PTl5NEe4
HGC27 LGNHzqe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTBwMEKgxtEhOC5yMESg{txOMnjFNlQ2QTd2N{i=
MKN45 HGMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;DOWlEPTB;MT6wNUDDuSByLkC1NUDPxE1?M{C3TFI1PTl5NEe4
MKN45 LGNWHZ[I5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHidGlpUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?=NVPHZllHOjR3OUe0O|g>
NUGC4 HGM3fvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;QPWlEPTB;MUSuNEDDuSB|LkmxN{DPxE1?MlraNlQ2QTd2N{i=
NUGC4 LGM1zzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fuemlEPTB;MUSuNEDDuSB3LkOyNUDPxE1?NFGzTnIzPDV7N{S3PC=>
A549MWrGeY5kfGmxbjDBd5NigQ>?NGXtUGExNjJ3L{CuOU8yKM7:TR?=Ml7LNlQhcA>?MlPUbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=>M{\JTlI1OzVzNEK1
H460MoLESpVv[3Srb36gRZN{[Xl?M4XpcVAvOjVxMD61M|Eh|ryPNUiwVFV7OjRiaB?=MmKwbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=>M{POUlI1OzVzNEK1
H661M3\0bGZ2dmO2aX;uJGF{e2G7MXuwMlI2NzBwNT:xJO69VQ>?NV\mTIlHOjRiaB?=M4XvbolvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?=MXmyOFM2OTR{NR?=
SASNXr1V4E1TnWwY4Tpc44hSXO|YYm=MmTSNE4zPS9yLkWvNUDPxE1?Mn25NlQhcA>?MUTpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl?NYDSVJF1OjR|NUG0NlU>
UT5NYDmeXoyTnWwY4Tpc44hSXO|YYm=NF3EcokxNjJ3L{CuOU8yKM7:TR?=MlT6NlQhcA>?M2XxdolvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?=NUTkbJhFOjR|NUG0NlU>
FaDuNGGx[2lHfW6ldHnvckBCe3OjeR?=MWCwMlI2NzBwNT:xJO69VQ>?M{DIXVI1KGh?MWnpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl?MVmyOFM2OTR{NR?=
RDMWLBdI9xfG:|aYOgRZN{[Xl?MofCNU8yNjVxMjFOwG0>NGnkTZQ4OiCqMnLySG1UVw>?MkTsbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=>MUOyN|Y5PDl{NR?=
TE671NWDXcnB5SXCxcITvd4l{KEG|c3H5MYqxM|EvPS9{IN88US=>MUC3NkBpMWfEUXNQMl;IbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=>M1Xx[lI{Pjh2OUK1
RH30 Mn3xRZBweHSxc3nzJGF{e2G7NXHFZZJXOS9zLkWvNkDPxE1?MkL0O|IhcA>?MYTEUXNQNGn3U41qdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3M1PxVVI{Pjh2OUK1
RMS13M3uySGFxd3C2b4Ppd{BCe3OjeR?=MoDnNU8yNjVxMjFOwG0>NVHBO|hYPzJiaB?=MmPFSG1UVw>?M1XkOolv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY>NFK3[m0zOzZ6NEmyOS=>
SUM149PTMYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>M2PCWFAvOyEQvF2=MUS3NkBpMWrlcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM>MUiyN|YxOTB5NB?=
MDA-MB-468MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MVSwMlMh|ryPNFmzbWk4OiCqNHzK[m1mdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN?NW\VOpR5OjN4MEGwO|Q>
MDA-MB-231M{TWSGNmdGxiVnnhZoltcXS7IFHzd4F6MUmwMlMh|ryPM4i0OlczKGh?NUPt[2R3\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K|NU\sS|JxOjN4MEGwO|Q>
SY5YMWDGeY5kfGmxbjDBd5NigQ>?M2fhRVEvPS9{LkWvOUDPxE1?M3vXblI1KGh?NUK4N|ZycW6mdXPld{BIOcLiY3XscE1kgWOuZTDhdpJme3RiYX7kJIFxd3C2b4Ppdy=>MoPMNlM{Pzh|NEG=
SKNBE(2c)NH\WNmhHfW6ldHnvckBCe3OjeR?=MWexMlUwOi53L{Wg{txONF;PcIEzPCCqMnLLbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?=NU\udGtbOjN|N{izOFE>
RDMkjLRZBweHSxc3nzJGF{e2G7M{X3cVMhyrWPNVO3NmV4OTJiaB?=NWDYdHd6TE2VTx?=MoHsd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO=MnjlNlM{ODB6MEm=
TP5014MXrBdI9xfG:|aYOgRZN{[Xl?M1LES|MhyrWPM2TJfFEzKGh?MWrEUXNQNVzTT2p5e2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM>MV2yN|MxODhyOR?=
HT1080MoPMRZBweHSxc3nzJGF{e2G7NVzaTYNVOyEEtV2=MWmxNkBpNYHTfI43TE2VTx?=NFLsUlN{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=>MnfZNlM{ODB6MEm=
A549Mlq3SpVv[3Srb36gRZN{[Xl?NWmxfHE6OC1|LkOg{txONVuydGVsPzJiaB?=NV7QUWdncW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuWMXmyN|I2QTV7MR?=
HCC827MX\GeY5kfGmxbjDBd5NigQ>?NEixPHgxNTNwMzFOwG0>MXO3NkBpNVLlRlltcW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuWMoLPNlMzPTl3OUG=
H3122M3fuSWZ2dmO2aX;uJGF{e2G7NWLWPFR2OC1|LkOg{txONEDlTFY4OiCqMY\pcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q>Mn7jNlMzPTl3OUG=
TALL-1M1TFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPTNgKBkc7:TR?=M17WWlch\A>?M{LvPYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>?NEHyV2szOzB|OEK3Ny=>
HPB-ALLMonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPKVGFuOeLCid88US=>M{Drc|ch\A>?NGnBZ2Fl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl?NH7le5MzOzB|OEK3Ny=>
DND41NHnST2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37JZlHjiIoQvF2=NH\XVlU4KGR?M2[yOIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>?MU[yN|A{QDJ5Mx?=
SUP-T1MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFu1OZMy6oDLzszNM2T4OFch\A>?M1\NfYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>?MlLzNlMxOzh{N{O=
PEERM1jRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mny1NgKBkc7:TR?=NE\DW3A4KGR?M1rBfYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>?M{HxO|I{ODN6Mkez
ALL-SILNIfGe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fUOlHjiIoQvF2=M1;y[Fch\A>?Mmrw[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6Mm\uNlMxOzh{N{O=
KE37NIPrTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXqx5qCK|ryPMk\IO{BlNILqV4Jl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl?MWOyN|A{QDJ5Mx?=
Karpas-45NYDhc4g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1y5c|HjiIoQvF2=NGfzVow4KGR?MVPk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk>M4e3dVI{ODN6Mkez
RPMI-8402NXjzdlVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDCNgKBkc7:TR?=M3n0dVch\A>?MnS3[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6NUT2XIRbOjNyM{iyO|M>
JurkatNHSwbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVToZWdUOeLCid88US=>MnPSO{BlNU\vdWdj\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7NE\mWHYzOzB|OEK3Ny=>
MOLT-4M4f6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUWx5qCK|ryPM1zUZVch\A>?NETGV5Rl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl?MVuyN|A{QDJ5Mx?=
PF-382MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDWVYEy6oDLzszNMYS3JIQ>M3\5c4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>?NH[1V5kzOzB|OEK3Ny=>
CCRF-CEMM33XU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFL6SXky6oDLzszNNUfLbFVMPyCmMVfk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk>MojONlMxOzh{N{O=
LOUCYMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnkfIZ3OeLCid88US=>M4[3V|ch\A>?MlfM[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6NHHWe4szOzB|OEK3Ny=>
MOLT-16MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moj1NgKBkc7:TR?=NWnaXWtqPyCmNUPXSW1P\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7MWqyN|A{QDJ5Mx?=
MM1SM2rXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3[xSFAuOiEQvF2=NXvi[JBCOjRiaB?=MnfjTWM2OD1yLkWg{txONFLvR20zOjh{OUKzOC=>
NCI-H929NEPKSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnk[nhtOC1{IN88US=>NIL2dlgzPCCqMl;lTWM2OD1yLkK1JO69VQ>?M2LvXVIzQDJ7MkO0
KMS12-BM NV3VcngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TvTFAuOiEQvF2=NWK4PJB1OjRiaB?=NVPkNpoxUUN3MP-8olIh|ryPMVGyNlgzQTJ|NB?=
MDA-MB-436Mo\RSpVv[3Srb36gRZN{[Xl?MljZNUDPxE1?NHvBU4YzPCCqNVHoPIxkemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=>MWOyNlQ5QDV7MB?=
SUM149PTNXjTT|lYTnWwY4Tpc44hSXO|YYm=MX:xJO69VQ>?MXWyOEBpMmTsdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?=NYDMcHc3OjJ2OEi1PVA>
SUM1315MO2M3r6e2Z2dmO2aX;uJGF{e2G7MYCxJO69VQ>?M4fqOVI1KGh?M3rYV5Jm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S=M2TNRlIzPDh6NUmw
HCC1937NIK2SlJHfW6ldHnvckBCe3OjeR?=NWnMdmZROSEQvF2=M1T0VFI1KGh?NX\rNZhYemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=>MVGyNlQ5QDV7MB?=
HCC827MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkS1NE0{KM7:TR?=M1e5bFczKGh?NVTsR4d{UUN3ME2wMlMh|ryPMYOyNVIzODR5NB?=
PC-9 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPuNE0{KM7:TR?=NFntS3o4OiCqMWTJR|UxRTBwODFOwG0>M4rRPVIyOjJyNEe0
LN229M1fyVmZ2dmO2aX;uJGF{e2G7NGXSNZkyKM7:TR?=NG\TeJk1QCCqMVnpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9vMoTsNlExPjJ7OUO=
U87M{K4NGZ2dmO2aX;uJGF{e2G7MmPJNUDPxE1?MUe0PEBpNFPhfYRqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:wM4Sw[|IyODZ{OUmz
U373NXzWNWNqTnWwY4Tpc44hSXO|YYm=MXWxJO69VQ>?NEDGO4o1QCCqNWX0OmtJcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?=Mnz6NlExPjJ7OUO=
SF767MlHXSpVv[3Srb36gRZN{[Xl?M1\6VVEh|ryPMmm3OFghcA>?NFfHRYVqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:wMUOyNVA3Ojl7Mx?=
Mel-JusoNYrhOI9xS2WubDDWbYFjcWyrdImgRZN{[Xl?MXewMlAy6oDVMUFihKnPxE1?NVPDb|Z3PzJiaB?=NWfIbYpxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=M2LKclIyODR6N{i1
518A2 M{DaN2NmdGxiVnnhZoltcXS7IFHzd4F6NVjKUZRnOC5yMfMAl|Ex6oDLzszNNXLHcVRwPzJiaB?=NGrOR|RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7MkHxNlExPDh5OEW=
Mel-Juso MWjGeY5kfGmxbjDBd5NigQ>?M1TwZVAvODBz4pETNgKBkc7:TR?=M2fSUVI1KGh?NFfxXmt{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTzMXKyNVA1QDd6NR?=
518A2NHe3SY9HfW6ldHnvckBCe3OjeR?=MljpNE4xODIkgKOx5qCK|ryPNWO1NGRWOjRiaB?=M{fPO5N2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO=MmrLNlExPDh5OEW=
PC3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LFSVI1cA>?MUnHTVUxyqB;IEGwNEBvVQ>?NI\VPHozODV3MUC2NS=>
U87MGMn3iSpVv[3Srb36gRZN{[Xl?MofRNE4yNTFizszNMWSyOQKBkWkEoB?=MV7EUXNQNYrK[4JGcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne=NHr3OXgyQTZ|M{[4Ny=>
U138MGM4DLOmZ2dmO2aX;uJGF{e2G7MnO4NE4yNTFizszNM{HPWFI16oDLaNMgNUeyVWtmTE2VTx?=MkTpbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd?NYPhN3dSOTl4M{O2PFM>
U118MGMX;GeY5kfGmxbjDBd5NigQ>?M4Tn[VAvOS1zIN88US=>NUDNWXBjOjUkgJnoxsA>NHfGZ5RFVVORNYnYe2FCcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne=NFj3SHIyQTZ|M{[4Ny=>
U87MGMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33kTWlEPTB;MD6xOEDPxE1?MYOxPVU5PDJ{Nx?=
IGROV-1NWH1SVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnFW2hKSzVyPUCuNFYh|ryPM{fJUlE6PTh2MkK3
DETROIT562M1vTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTBwMUOg{txOMorzNVk2QDR{Mke=
PC3 NWLudG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;3cVFKSzVyPUCuNVAh|ryPMnfaNVk2QDR{Mke=
SKOV-3M3W1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTBwMUKg{txONH3zS4UyQTV6NEKyOy=>
HUVECMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17FcmlEPTB;MD6wPEDPxE1?NU[xZYdwOTl3OESyNlc>
UCH-1 MlvQSpVv[3Srb36gRZN{[Xl?MnTlNE02KM7:TR?=MWjpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKGKxdHigRWtVKGGwZDDtWG9TKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzMniyNVk2Ojh2NEG=
UCH-1 M2jLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHIXmVGOC5yMT2xNEDPxE1?NHW3VlI3KGR?MYPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk>M2W2b|E6PTJ6NESx
UCH-1 MlXWRZBweHSxc3nzJGF{e2G7NETEcpoxNjFvMUCg{txONW\qNYd3OjRiaB?=NVzBTFFRTE2VTx?=Mnr3bY5lfWOnczDhdI9xfG:|aYO=MVexPVUzQDR2MR?=

... Click to View More Cell Line Experimental Data

In vivo When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
Features The first potent, synthetic mTOR inhibitor.

Protocol(Only for Reference)

Kinase Assay: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

Cell Assay: [2]

Cell lines U87MG cells
Concentrations 0.5 μM
Incubation Time 24 hours
Method U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

Animal Study: [2]

Animal Models 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
Formulation 50% DMSO
Dosages 5 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Knight ZA, et al. Cell, 2006, 125(4), 733-747.

[2] Fan QW, et al. Cancer Cell, 2006, 9(5), 341-349.

view more

Chemical Information

Download PI-103 SDF
Molecular Weight (MW) 348.36
Formula

C19H16N4O3

CAS No. 371935-74-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

Customer Product Validation (4)


Click to enlarge
Rating
Source Mol Carcinog 2012 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog 2012 ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Product Use Citation (21)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Recently Viewed Items

Tags: buy PI-103 | PI-103 supplier | purchase PI-103 | PI-103 cost | PI-103 manufacturer | order PI-103 | PI-103 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us